Enanta Pharmaceuticals, Inc. (ENTA) Stock Analysis & Investment Frameworks
Enanta Pharmaceuticals, Inc. (ENTA) stock analysis on Invetso. Review Enanta Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Enanta Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Enanta Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $331.30M
- Revenue: $65.32M
- ROE: -61.84%
- ROIC: -23.81%
- Dividend Yield: N/A
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.